VERNON HILLS, Ill., June 1, 2017 /PRNewswire/ --áNexus Pharmaceuticals announced today the immediate availability in the United States of Sodium Nitroprusside Injection. Nexus Pharmaceuticals' Sodium Nitroprusside Injection is available as a single dose vial containing 50 mg per 2mL (25mg/mL) and is an AP Rated generic equivalent of Nitropress«.
About Nexus Pharmaceuticals Inc.
Nexus Pharmaceuticals (www.nexuspharma.net) is a U.S. based healthcare company that specializes in developing and marketing generic sterile injectable products. Through our high quality generic products, Nexus Pharmaceuticals is committed to providing patients with affordable prescription medicines that lower healthcare costs and provide a better quality of life. The company's headquarters is in Vernon Hills, Illinois.
Nitropress« is a registered trademark of Hospira Inc.
Media ContactNexus Pharmaceuticals Inc. Ayesha Ahmed[email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nexus-pharmaceuticals-receives-fda-approval-for-sodium-nitroprusside-injection-300467416.html
SOURCE Nexus Pharmaceuticals Inc.
Subscribe to our Free Newsletters!
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...
Spinal anesthesia and epidural anesthesia are types of regional anesthesia in which when a drug is ...
Colorectal cancer is a cancer that starts in the colon or the rectum. Colo-rectal cancer is the ...View All